Net loss attributable to BioCorRx Inc. decreased to $3,440,146 in 2025 from $5,106,124 in 2024. Total net revenues surged to $797,244 in 2025, a 10,301.1% increase from $7,665 in 2024, primarily due to the acquisition of Lucemyra assets. Grant income significantly increased to $2,435,848 in 2025 from $1,473,276 in 2024, supporting BICX104 research for methamphetamine use disorder (MUD). The company acquired assets and assumed liabilities related to Lucemyra, an FDA-approved prescription medication for opioid withdrawal, from USWM, LLC on March 4, 2025, for an upfront purchase price of $400,000 and a 3% royalty on net sales. Operating expenses increased by $498,716 to $5,628,886 in 2025, mainly due to higher consulting, research and development, and royalty expenses, partially offset by decreased stock-based compensation. The company continues to face substantial doubt about its ability to continue as a going concern, with a working capital deficit of $7,491,731 and an accumulated deficit of $86,649,288 as of December 31, 2025. Management identified material weaknesses in internal control over financial reporting due to inadequately documented policies, insufficient GAAP experience for complex transactions, and insufficient staff for optimal segregation of duties.